Venus Remedies Ltd, a leading manufacturer of oncology drugs, has obtained marketing authorizations for two important cancer treatments, thereby enhancing its global footprint. The approvals include bortezomib in the Philippines and carboplatin in Morocco, bringing the company’s oncology portfolio to a total of 508 approvals across 76 countries.
Saransh Chaudhary, President of Global Critical Care at Venus Remedies, stated, “These approvals are crucial to our strategy for expanding our oncology range and addressing the rising global demand for cancer therapies. We are on track to become the premier oncology supplier in Southeast Asia.”
The Philippine market, the second largest in the ASEAN region, is projected to grow from US $400 million in 2022 to US $790 million by 2030. The approval of bortezomib will enhance the company’s capability to provide advanced cancer treatments in Southeast Asia.
In Morocco, where the oncology drug market is expected to reach US $150.8 million by 2029, the approval of carboplatin will strengthen Venus Remedies’ presence in the African oncology market.
Aditi K. Chaudhary, President of International Business, highlighted the company’s commitment to global health initiatives, stating, “These authorizations reflect our dedication to delivering innovative and accessible healthcare solutions worldwide.”
As reported by press release, Venus Remedies now holds 15 authorizations in Morocco and 69 in the Philippines. These achievements contribute to India’s expanding pharmaceutical exports, which reached US $27.9 billion in the 2023-24 fiscal year. The global oncology market is anticipated to grow significantly, reaching US $518.25 billion by 2032.